Please provide your email address to receive an email when new articles are posted on . Autologous dermal fibroblasts may decrease risk of rotator cuff retears after arthroscopic rotator cuff repair ...

2.1.1 Lipoatrophy is the localised loss of fat from within subcutaneous tissue. It can be a congenital condition or can be associated with subcutaneous injection sites. Facial lipoatrophy is commonly ...

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company, announced the granting of two patents in Europe related to its multi-needle dermal injection technologies. The first patent ...

A new study examines dermal injections and their impact on skin aging. Chronic exposure of human skin to ultraviolet light causes premature aging, or photoaging. As the skin undergoes photoaging, type ...

With exclusive U.S. rights to RCI-02 patents, RepliCel edges its nearest-term commercial asset closer to launch in large aesthetic market In the development of propriety cell therapy products ...

Two European firms team up to lead RepliCel's next-generation dermal injector (RCI-02) to market-ready status VANCOUVER, Feb. 28, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP ...

Current evidence on the efficacy of deep dermal injection of non-absorbable gel polymer (NAGP) for HIV-related facial lipoatrophy is adequate. With regard to safety, infections that may need surgical ...

"The execution of these agreements covers what we believe to be the final stages needed to prepare RCI-02 for a market authorization application in the form of a CE mark in Europe," stated RepliCel ...